An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

The International Prognostic Index (IPI) has been the basis for determining prognosis in patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20 years. Using raw clinical data from the National Comprehensive Cancer Network (NCCN) database collected during the rituximab era, we built an e...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Zhou, Zheng, Sehn, Laurie H., Rademaker, Alfred W., Gordon, Leo I., LaCasce, Ann S., Crosby-Thompson, Allison, Vanderplas, Ann, Zelenetz, Andrew D., Abel, Gregory A., Rodriguez, Maria A., Nademanee, Auayporn, Kaminski, Mark S., Czuczman, Myron S., Millenson, Michael, Niland, Joyce, Gascoyne, Randy D., Connors, Joseph M., Friedberg, Jonathan W., Winter, Jane N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2014
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5527396/
https://ncbi.nlm.nih.gov/pubmed/24264230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-09-524108
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg